Loading organizations...
§ Venture Capital · Beijing, China
Invests in health industry, focusing on biotechnology, pharmaceuticals, and medical services.
The Beijing Pharmaceutical and Health Industry Investment Fund operates as a venture capital entity, strategically investing in the medical and health sectors. It focuses on pharmaceutical companies and biotechnology firms, particularly those advancing AI-driven drug development. The fund's core strategy involves backing enterprises contributing to healthcare evolution.
This fund was established as a critical component of a broader governmental initiative in Beijing, directing resources toward key industrial domains. Launched as one of several major industrial funds, it began with a substantial initial capital objective to bolster Beijing's industrial capacity. Its formation stems from a policy-driven vision to elevate the region's pharmaceutical and health technology landscape.
The fund provides essential growth capital to diverse medical and health-related enterprises. Its overarching vision is to stimulate a dynamic, innovative pharmaceutical, and health industry within Beijing. Through targeted investments, the fund aims to enhance the region's standing as a leading center for healthcare innovation, fostering new medical solutions.
Key people at Beijing Pharmaceutical and Health Industry Investment Fund.
Beijing Pharmaceutical and Health Industry Investment Fund has 4 tracked investments across 4 companies. The latest tracked deal is $43.4M Series A in Zhiran Medical in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 11, 2026 | Zhiran Medical | $43.4M Series A | CAS Star, IDG Capital, Legend Capital | Apricot Capital, Baidu Ventures, Beijing Medical And Health Industry Investment Fund, BioVenture, Jiayin Capital, Lenovo Capital And Incubator Group (LCIG), Longzhu Capital, Sequoia Capital, Shunwei Capital, China Life Capital, DragonBall Capital |
| Feb 11, 2026 | BCIFlex | $4.3B Series A | 中科创星 | Baidu Ventures, DragonBall Capital, Hongshan Capital Group (Sequoia Capital China), IDG Capital, JIA YIN Capital, Legend Capital, Lenovo Capital, Shunwei Capital, Xingze Capital, Yuan Sheng Capital |
| Jan 13, 2026 | Oricell Therapeutics | $70.0M Series C | Beijing Pharmaceutical And Health Industry Investment Fund, William HU | NGS Super, Talon Capital |
| Dec 24, 2025 | DP Technology | $113.9M Series C | — | Beijing Artificial Intelligence Industry Investment Fund |
Key people at Beijing Pharmaceutical and Health Industry Investment Fund.